Development and Challenges of Synthetic Retinoid Formulations in Cancer

Simple item page
dc.contributor.authorAssi, Sara
dc.contributor.authorEl-Hajj, Hiba Ahmad
dc.contributor.authorHayar, Berthe
dc.contributor.authorPisano, Claudio C.P.
dc.contributor.authorSaad, Walid S.
dc.contributor.authorDarwiche, Nadine D.
dc.contributor.departmentDepartment of Mechanical Engineering
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentBiochemistry and Molecular Genetics
dc.contributor.departmentDepartment of Chemical and Petroleum Engineering
dc.contributor.facultyMaroun Semaan Faculty of Engineering and Architecture (MSFEA)
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:33:30Z
dc.date.available2025-01-24T11:33:30Z
dc.date.issued2023
dc.description.abstractRetinoids represent a class of chemical compounds derived from or structurally and functionally related to vitamin A. Retinoids play crucial roles in regulating a range of crucial biological processes spanning embryonic development to adult life. These include regulation of cell proliferation, differentiation, and cell death. Due to their promising characteristics, retinoids emerged as potent anti-cancer agents, and their effects were validated in vitro and in vivo preclinical models of several solid and hematological malignancies. However, their clinical translation remained limited due to poor water solubility, photosensitivity, short half-life, and toxicity. The development of retinoid delivery formulations was extensively studied to overcome these limitations. This review will summarize some preclinical and commercial synthetic retinoids in cancer and discuss their different delivery systems. © 2023 Bentham Science Publishers.
dc.identifier.doihttps://doi.org/10.2174/1567201819666220810094708
dc.identifier.eid2-s2.0-85153582836
dc.identifier.pmid35950256
dc.identifier.urihttp://hdl.handle.net/10938/27994
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Drug Delivery
dc.sourceScopus
dc.subjectCancer
dc.subjectDelivery system
dc.subjectDevelopment
dc.subjectDrug
dc.subjectFormulation
dc.subjectSynthetic retinoid
dc.subjectAntineoplastic agents
dc.subjectCell differentiation
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectRetinoids
dc.subjectVitamin a
dc.subjectAdarotene
dc.subjectAlbumin
dc.subjectBexarotene
dc.subjectCopolymer
dc.subjectDoxorubicin
dc.subjectFenretinide
dc.subjectGel
dc.subjectLenalidomide
dc.subjectLiposome
dc.subjectMicrosphere
dc.subjectNanoparticle
dc.subjectPaclitaxel
dc.subjectPhospholipid
dc.subjectPolyglactin
dc.subjectRetinoic acid
dc.subjectRetinoic acid binding protein
dc.subjectRetinoid
dc.subjectRetinoid x receptor
dc.subjectRetinoid x receptor alpha
dc.subjectSilicon dioxide
dc.subjectSoluplus
dc.subjectSt1926 nanoparticle
dc.subjectTamibarotene
dc.subjectTrifarotene
dc.subjectUnclassified drug
dc.subjectAntineoplastic agent
dc.subjectRetinol
dc.subjectAcne vulgaris
dc.subjectAntineoplastic activity
dc.subjectAqueous solution
dc.subjectCell death
dc.subjectCell proliferation
dc.subjectCommercial phenomena
dc.subjectDrug delivery system
dc.subjectDrug formulation
dc.subjectDrug half life
dc.subjectHuman
dc.subjectHypertriglyceridemia
dc.subjectHypothyroidism
dc.subjectIn vitro study
dc.subjectIn vivo study
dc.subjectMalignant neoplasm
dc.subjectMicelle
dc.subjectNanoencapsulation
dc.subjectPhotosensitivity
dc.subjectPreclinical study
dc.subjectReview
dc.subjectT cell lymphoma
dc.subjectWater solubility
dc.subjectMetabolism
dc.subjectNeoplasm
dc.titleDevelopment and Challenges of Synthetic Retinoid Formulations in Cancer
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2023-1101.pdf
Size:
733.85 KB
Format:
Adobe Portable Document Format
Download

Collections

Department of Mechanical Engineering
Biochemistry and Molecular Genetics
Department of Chemical and Petroleum Engineering
Experimental Pathology, Microbiology, and Immunology